Home Cart Sign in  
Chemical Structure| 13826-27-2 Chemical Structure| 13826-27-2

Structure of 13826-27-2

Chemical Structure| 13826-27-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 13826-27-2 ]

CAS No. :13826-27-2
Formula : C12H8B2O4
M.W : 237.81
SMILES Code : B1(B2OC3=CC=CC=C3O2)OC4=CC=CC=C4O1
MDL No. :MFCD09842343
InChI Key :WYBQOWXCLDXZNR-UHFFFAOYSA-N
Pubchem ID :3488065

Safety of [ 13826-27-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 13826-27-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 12
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 66.9
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

36.92 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.66
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.98
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.83
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.22
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.25

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-4.05
Solubility 0.0213 mg/ml ; 0.0000896 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-4.12
Solubility 0.0179 mg/ml ; 0.0000751 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.95
Solubility 0.0266 mg/ml ; 0.000112 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.15 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.0

Application In Synthesis of [ 13826-27-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 13826-27-2 ]

[ 13826-27-2 ] Synthesis Path-Downstream   1~10

  • 2
  • [ 76-09-5 ]
  • [ 13826-27-2 ]
  • 2,4,6-triphenyl-1-(tetrahydro-2H-pyran-4-yl)pyridin-1-ium tetrafluoroborate [ No CAS ]
  • [ 1131912-76-9 ]
  • 4
  • [ 25637-18-7 ]
  • [ 13826-27-2 ]
  • [ 1131912-76-9 ]
  • 5
  • [ 76-09-5 ]
  • [ 13826-27-2 ]
  • 4-methoxybenzyl methyl oxalate [ No CAS ]
  • [ 475250-52-3 ]
  • 6
  • [ 76-09-5 ]
  • [ 13826-27-2 ]
  • 3-chlorobenzoic tetrahydro-2H-pyran-4-carboxylic peroxyanhydride [ No CAS ]
  • [ 1131912-76-9 ]
  • 7
  • [ 25637-16-5 ]
  • [ 76-09-5 ]
  • [ 13826-27-2 ]
  • [ 1131912-76-9 ]
  • 8
  • [ 76-09-5 ]
  • [ 111-83-1 ]
  • [ 13826-27-2 ]
  • [ 66217-56-9 ]
YieldReaction ConditionsOperation in experiment
81% In a glove box under a nitrogen atmosphere, B2cat2 (0.45 mmol, 1.5 equiv, 107.0 mg), AIBN (0.33 mmol, 1.1 equiv, 54.2 mg), 2 mL of solvent N,N-dimethylacetamide, TTMSS (0.33 mmol, 1.1 equiv, 101.8 μL) and bromo-n-octane (0.3 mmol, 52.3 μL). The capped Schlenk bottle was removed from the glove box, and the reaction mixture was stirred at 80 C for 6 hours. After cooling to room temperature, pinacol (141.8 mg, 4.0 equivalents) was added to the reaction flask, 1.0 mL of triethylamine was added, and the mixture was stirred at room temperature for 1 hour. Subsequently, the reaction mixture was transferred to a 125 mL separatory funnel through 30 mL of ethyl acetate, and then 30 mL of water was added thereto for water washing, and then the aqueous phase was extracted 3 times with 30 mL of ethyl acetate. After washing with 100 mL of saturated saline, the organic phase was dried over anhydrous sodium sulfate and filtered, and then 2.0 mL of TBAF (1 mol / L in THF) was added to remove silicon-containing by-products generated by the reaction. Add a small spoon of 200-300 mesh silica gel, remove the solvent under reduced pressure, adsorb the mixture onto silica gel, and purify by column chromatography. The developing agent used is petroleum ether / ethyl acetate volume ratio 50: 1 30: 1 mixed solution to obtain the desired product pinocyl alcohol n-octyl borate 58.4mg, yield 81%.
  • 9
  • [ 76-09-5 ]
  • [ 629-27-6 ]
  • [ 13826-27-2 ]
  • [ 66217-56-9 ]
YieldReaction ConditionsOperation in experiment
80% In the dried reaction tube, add B2cat2 (4.0eq., 576mg), nBu4NBF4 (50mol%, 99mg), and add the electrode material to the above reaction tube, seal the reaction system, and replace it with inert gas (Ar) three times. A syringe was used to inject 1-iodooctane (0.6 mmol, 144 mg) and DMF (6 mL) into the above three-port reaction tube, and the reaction was conducted for 12 minutes at 25 C. with a current of 200 mA. After the reaction, pinacol (8.0eq., 567mg) and Et3N (1.5mL) were injected into the reaction system and stirred for 1h. The reaction was terminated, and the reaction solution was quenched with 15 mL of saturated sodium chloride solution, and then extracted with ethyl acetate (15 mL×3) for multiple times. The organic phases were combined, and the solvent was removed on the rotary evaporator. Finally, it is separated by silica gel column chromatography (eluent: ethyl acetate: petroleum ether = 1:150) to obtain 4,4,5,5-tetramethyl-2-octyl-1,3,2-di Oxaborane (116 mg, isolated yield: 80%), the compound is a colorless liquid.
  • 10
  • [ 76-09-5 ]
  • [ 111-85-3 ]
  • [ 13826-27-2 ]
  • [ 66217-56-9 ]
 

Historical Records

Categories